Spark Therapeutics is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases.

TypePublic
HQPhiladelphia, US
Founded2013
Size (employees)213 (est)
Websitesparktx.com
Spark Therapeutics was founded in 2013 and is headquartered in Philadelphia, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Spark Therapeutics

Jeffrey D. Marrazzo

Jeffrey D. Marrazzo

Co-Founder, President and CEO
J. Fraser Wright

J. Fraser Wright

Scientific Co-Founder and CTO
Katherine A. High

Katherine A. High

Scientific Co-Founder
Show more

Spark Therapeutics Office Locations

Spark Therapeutics has an office in Philadelphia
Philadelphia, US (HQ)
3737 Market St
Show all (1)
Report incorrect company information

Spark Therapeutics Financials and Metrics

Spark Therapeutics Revenue

Spark Therapeutics's revenue was reported to be $12.07 m in FY, 2017
USD

Revenue (Q2, 2018)

40.9 m

Gross profit (Q2, 2018)

40.5 m

Gross profit margin (Q2, 2018), %

99%

Net income (Q2, 2018)

33.8 m

EBIT (Q2, 2018)

(83.5 m)

Market capitalization (20-Sep-2018)

2.1 b

Closing stock price (20-Sep-2018)

57.2

Cash (30-Jun-2018)

201.1 m

EV

1.9 b
Spark Therapeutics's current market capitalization is $2.1 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

633.9 k22.1 m20.2 m12.1 m

Revenue growth, %

3380%(9%)

General and administrative expense

7.9 m23.4 m48.1 m111.1 m

R&D expense

16.4 m46 m86.4 m135.2 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

2.3 m1.3 m1.3 m1.3 m1.3 m1.3 m1.3 m1.5 m15.7 m40.9 m

Cost of goods sold

121 k390 k

Gross profit

15.6 m40.5 m

Gross profit Margin, %

99%99%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

74.6 m293.5 m58.9 m96.7 m

Accounts Receivable

244.4 k16.9 m16.8 m

Current Assets

77.4 m311.6 m314.6 m533.2 m

PP&E

12.7 m17 m19.8 m61.7 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

234.4 m223 m212.2 m275 m225 m90.6 m27.5 m36.8 m127.7 m201.1 m

Accounts Receivable

669.4 k933.1 k1.3 m812.8 k1.2 m1 m5.9 m5 m

Inventories

5.6 m12.7 m

Current Assets

235.9 m225.1 m214.3 m277.8 m335.3 m309.2 m263.4 m226.3 m621 m691.6 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(24.3 m)(47.1 m)(123.7 m)(253.5 m)

Depreciation and Amortization

169.8 k1.7 m3.6 m4.9 m

Accounts Payable

2.3 m9.1 m10 m13 m

Cash From Operating Activities

10.4 m(47.5 m)(80.4 m)(154.5 m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Net Income

(9.7 m)(24.1 m)(41 m)(25.6 m)(54.3 m)(86.8 m)(52.3 m)(126.6 m)(46.4 m)33.8 m

Depreciation and Amortization

370.6 k797.2 k1.2 m744.1 k1.7 m2.6 m1 m2.2 m1.5 m3.1 m

Inventories

(5.6 m)(12.7 m)

Accounts Payable

870.4 k3.2 m7.7 m(1.1 m)(2 m)4.2 m(2.7 m)4.8 m(8.4 m)(8 m)
USDY, 2018

EV/EBIT

-23.3 x

EV/CFO

284.2 x

Financial Leverage

1.3 x
Show all financial metrics

Spark Therapeutics Operating Metrics

FY, 2016

Patents and Patent Applications

297
Show all operating metrics
Report incorrect company information

Spark Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Spark Therapeutics News and Updates

Spark Therapeutics Announces Positive CHMP Opinion for One-time Gene Therapy LUXTURNA® (voretigene neparvovec) in the European Union

LUXTURNA would be first gene therapy for a genetic disease approved in both U.S. and EU

Spark Therapeutics stock plummets 28% premarket on hemophilia trial's patient safety concerns

Spark Therapeutics Inc. shares dropped 28% in Tuesday premarket trade after the company said two patients in its hemophilia phase 1/2 trial had a concerning immune response, one of whom was hospitalized as a result. The company plans a phase 3 trial for the fourth quarter of this year. Twelve patie…

Spark Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Progress

As of July 13, 2018, preliminary Phase 1/2 data for investigational SPK-8011 for hemophilia A show:

Spark Therapeutics gene therapy reduces bleeding in hemophilia A trial

Spark Therapeutics, the biotechnology company focused on gene therapy, said its experimental treatment for hemophilia A reduced bleeds and the need for therapeutic infusions by 97 percent in a trial of 12 patients.

Spark Therapeutics wurde vom Philadelphia Business Journal zum zweiten Mal in Folge als einer von Philadelphias „besten Arbeitgeber“ ausgezeichnet

PHILADELPHIA , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), ein voll integriertes Gentherapie-Unternehmen, das infrage stellt, dass genetische Krankheiten unvermeidbar sind, gab heute bekannt, dass es von Philadelphia Business Journal zum zweiten Mal in Folge als einer von …
Show more
Report incorrect company information

Spark Therapeutics Company Life and Culture

Report incorrect company information